Source:http://linkedlifedata.com/resource/pubmed/id/20563259
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
2010-6-21
|
pubmed:abstractText |
Adverse effects of erythropoietin (EPO) on tumor progression and survival were observed in recent phase 3 oncology trials. However, mechanisms remain poorly understood. We tested the effects of exogenous EPO on murine B16F10 melanoma growth in a subcutaneous tumor transplant model, and for the first time, in a model of spontaneous tumor formation within autochthonous epithelial tissues using murine mammary tumor virus promoter polyoma virus middle T antigen (MMTV-PyMT) transgenic mice. EPO receptor (EPOR) messenger RNA (mRNA) was detectable in both B16F10 tumors and mammary tumors from MMTV-PyMT mice but was 0.12 +/- 0.02% and 1.3 +/- 0.91% of the EPOR mRNA level in murine erythroid HCD-57 cells, respectively. B16F10 tumor growth rates in mice treated for 3 weeks with 30 microg/kg per week of darbepoetin alpha, 0.41 inverse days (range, 0.05-0.69 inverse days; n = 16), were similar to tumor growth rates observed in mice treated with PBS, 0.42 inverse days (range, 0.10-0.69 inverse days; n = 17). In contrast, darbepoetin alpha raised hematocrit levels to 0.593 (maximum, 0.729) compared with 0.448 (maximum, 0.532) in PBS-treated mice (P = .0004). In MMTV-PyMT mice, the weights of tumor-bearing mammary glands in mice treated for 6 weeks with 30 microg/kg per week of darbepoetin alpha, 3.37 g (range, 1.94-5.81 g; n = 27), did not significantly differ from the weights in PBS-treated mice, 3.76 g (range, 2.30-6.33 g; n = 26). In contrast, darbepoetin alpha raised hematocrit levels to 0.441 (maximum, 0.606) compared with 0.405 (maximum, 0.492) in PBS-treated mice (P = .05). Thus, effects of exogenous EPO on tumor growth were not recapitulated in these murine tumor models.
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/20563259-11250712,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20563259-11259101,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20563259-11414753,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20563259-12807756,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20563259-1312220,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20563259-1420106,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20563259-14463220,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20563259-14575968,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20563259-14578209,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20563259-16087945,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20563259-16698707,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20563259-1705834,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20563259-17206489,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20563259-17312332,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20563259-17579721,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20563259-17582631,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20563259-18227526,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20563259-18314434,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20563259-18676735,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20563259-18714393,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20563259-19040789,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20563259-19410717,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20563259-9270023
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:status |
PubMed-not-MEDLINE
|
pubmed:issn |
1936-5233
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:volume |
3
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
176-80
|
pubmed:year |
2010
|
pubmed:articleTitle |
Limitations of a murine transgenic breast cancer model for studies of erythropoietin-induced tumor progression.
|
pubmed:affiliation |
Department of Medicine/Hematology and the Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA, USA.
|
pubmed:publicationType |
Journal Article
|